IRIS
FERONE, DIEGO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 34.560
AS - Asia 114
SA - Sud America 28
AF - Africa 2
NA - Nord America 1
Totale 34.705
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 34.558
CN - Cina 72
BR - Brasile 22
VN - Vietnam 21
SG - Singapore 17
EC - Ecuador 5
ID - Indonesia 3
AR - Argentina 1
BD - Bangladesh 1
EG - Egitto 1
FI - Finlandia 1
RU - Federazione Russa 1
US - Stati Uniti d'America 1
ZA - Sudafrica 1
Totale 34.705
Salva come PNG Salva come JPEG
Città #
Genova 21.519
Genoa 8.309
Rapallo 2.417
Vado Ligure 2.268
Bordighera 39
Beijing 30
Singapore 12
Ho Chi Minh City 7
Hanoi 4
Ninh Bình 3
Rome 3
Turin 3
Da Nang 2
Guayaquil 2
Hải Dương 2
São Paulo 2
Ashburn 1
Bắc Giang 1
Cairo 1
Can Tho 1
Cape Town 1
Chacabuco 1
Elói Mendes 1
Embu das Artes 1
Guarulhos 1
Hangzhou 1
Ibaté 1
Itabuna 1
Ituiutaba 1
Jaboatão dos Guararapes 1
Jaguariúna 1
Jakarta 1
Khimki 1
Lappeenranta 1
Maricá 1
Osasco 1
Pindamonhangaba 1
Pinhais 1
Piracicaba 1
Quito 1
Quận Chín 1
Rio Verde 1
Rio de Janeiro 1
Sarandi 1
Surabaya 1
São Bernardo do Campo 1
São Carlos 1
Xaxim 1
Totale 34.654
Salva come PNG Salva come JPEG
Nome #
Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins 283
Diffuse Endocrine System, Neuroendocrine Tumors and Immunity: What's New? 205
Autonomic nervous system and cardiovascular risk assessment during one year of growth hormone (GH) replacement therapy in adults with GH deficiency. 199
SOMATOSTATIN AND DOPAMINE RECEPTOR INTERACTION IN PROSTATE AND LUNG CANCER CELL LINES 195
Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy? 192
Effect of environment on growth: auxological and hormonal parameters in African and Italian children 190
Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study 190
Diabetes secondary to neuroendocrine gastroenteropancreatic tumors 187
Conventional and nuclear medicine imaging in Ectopic Cushing's syndrome: A systematic review 186
Pituitary image: pituicytoma. 183
Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. 183
Increased mammographic breast density in acromegaly: quantitative and qualitative assessment. 178
Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells 177
Neuroendocrine-immune interactions: the role of cortistatin/somatostatin system 174
Current perspectives in obesity management: unraveling the impact of different therapy approach in real life obesity care 173
Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas 171
Acromegaly is associated with increased cancer risk: A survey in Italy 170
Computed tomography colonography in acromegaly 169
Calcitonin assay in wash-out fluid after fine-needle aspiration biopsy in patients with a thyroid nodule and border-line value of the hormone 169
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology 168
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids 163
Partial visual recovery from radiation-induced optic neuropathy after hyperbaric oxygen therapy in a patient with Cushing disease 162
Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases 162
The pathology of the ulnar nerve in acromegaly. 162
Emerging targets in pituitary adenomas: role of the CXCL12/CXCR4-R7 system 161
Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas 160
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs? 159
Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS) 159
Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study 158
Adult iatrogenic Cushing's syndrome induced by topical skin corticosteroid misuse 157
(99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy. 156
Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth. 156
Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience. 156
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? 155
Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors 153
Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation 152
A unique association of clinical "persistent müllerian duct syndrome" and syringoid carcinoma of the perineal-scrotal skin: a consequence of urologic surgery? 152
Hormone receptors analysis in idiopathic progressive subglottic stenosis 151
Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient 150
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives 150
Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients 149
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogs and dopastatins 148
Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system 148
Endoscopic endonasal transsphenoidal approach: An additional reason in support of surgery in the management of pituitary lesions. 148
"Present and future of immunotherapy in Neuroendocrine Tumors" 148
Grade increases in gastroenteropancreatic neuroendocrine tumor metastases compared to the primary tumor 147
High prevalence of vitamin D deficiency and its association with left ventricular dilation: an echocardiography study in elderly patients with chronic heart failure 146
Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: in vivo and in vitro studies. 146
Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. 146
Rare diseases in clinical endocrinology: A taxonomic classification system 145
Vasopressin levels in Cushing’s disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing’s disease. 144
Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. 144
Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas 144
KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment ? 143
One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients 143
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms 143
Dopamine receptor expression and function in corticotroph ectopic tumors. 142
Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR 142
Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease. 141
Initial staging of lymphoma with octreotide and other receptor imaging agents. 141
Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. 140
A pilot study on nerve ultrasound in acromegaly 139
Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing’s disease before and after corticotropin-releasing hormone administration. 139
Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. 138
Managing Cushing's disease: The state of the art 138
Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible? 138
Somatostatin receptor scintigraphy in thoracic diseases 137
Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities 137
Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study. 137
On-field evaluation of a ultra-rapid fluorescence immunoassay as a frontline test for SARS-CoV-2 diagnostic 136
Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population 136
Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study 136
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database 136
Leptin, ghrelin, and adiponectin evaluation in transsexual subjects during hormonal treatments 135
Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells 135
Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency 135
Musculoskeletal complications of acromegaly: what radiologists should know about early manifestations. 135
Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly 134
Doe4s biopsy reliably identify grade in gastro-entero-pancreatic neuroendocrine tumors? 134
Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures 134
Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center 133
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab 133
Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review. 133
Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients 133
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. 132
Ectopic Cushing and other paraneoplastic syndromes in thoracic neuroendocrine tumors 132
Systemic complications of acromegaly: epidemiology, pathogenesis, and management 131
Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies 131
Sympathovagal imbalance in acromegalic patients 130
Somatostatin receptor ligands in the treatment of acromegaly 130
Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly 130
Somatostatin receptor expression in thymic tumors. 129
Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly 129
Long-term outcome of low-activity radioiodine administration preceded by adjuvant recombinant human TSH pretreatment in elderly subjects with multinodular goiter. 128
Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas 128
P68 Insulin-like growth factor (IGF) binding protein-3 inhibits IGF-II-stimulated IRS-1/PI-3-kinase activity and cell growth in human non-small cell lung cancer (NSCLC) cell lines 128
Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data. 127
Zebrafish as an innovative model for neuroendocrine tumors 127
Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. 125
Sonographic depiction of trigger fingers in acromegaly. 125
Totale 15.097
Salva come PNG Salva come JPEG
Categoria #
all - tutte 118.977
article - articoli 117.886
book - libri 0
conference - conferenze 577
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 514
Totale 237.954
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.957 0 0 0 331 201 191 100 291 201 284 190 168
2021/20223.426 98 221 283 437 90 251 257 736 174 317 163 399
2022/20232.958 329 208 39 270 442 524 23 219 531 26 302 45
2023/20241.652 90 221 39 186 131 283 108 69 100 66 100 259
2024/20255.496 153 423 155 368 781 573 564 784 247 267 502 679
2025/20263.242 1.078 332 1.010 822 0 0 0 0 0 0 0 0
Totale 35.296